Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
23 hedge funds and large institutions have $5.27M invested in Vyant Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
21% less funds holding
Funds holding: 29 → 23 (-6)
37% less capital invested
Capital invested by funds: $8.41M → $5.27M (-$3.15M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$302K |
| 2 |
State Street
Boston,
Massachusetts
|
+$35.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.5K |
| 5 |
Millennium Management
New York
|
+$9.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$210K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$97K |
| 3 |
VF
Virtu Financial
New York
|
-$77K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$49K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$37K |
VYNT Hedge Fund Activity: Q3 2021 in Review
23 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2021, worth a combined $5.27M — down 37% from $8.41M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VYNT and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $302K. The largest seller was NewEdge Advisors, exiting entirely with an estimated $210K sold.
- 23 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2021, down from 29 in Q2 2021.
- Funds reported $5.27M of Vyant Bio, Inc. Common Stock stock for Q3 2021, down 37% quarter-over-quarter.
- 1 fund opened new Vyant Bio, Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of -6 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2021 was Renaissance Technologies, an estimated $302K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2021 was NewEdge Advisors, an estimated $210K sold.
Based on aggregated 13F filings for Q3 2021.